MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), a pre-clinical-stage pharmaceutical development company, announced on Thursday that it has named Dr Itzchak Angel as its new chief scientific advisor.

Dr Angel has more than 40 years of preclinical, clinical and regulatory experience. He has served as an external consultant in strategic drug development and innovation at Teva, and founded and served as an officer and director of several pharma start-ups. He has worked as vice president for Research and Development at D-Pharm Biopharmaceuticals; president and chief executive officer of stem-cell company Accellta; vice president for Research and Development at Proteologics Ltd and at Galmed Pharmaceuticals and head of Discovery and Research and Development Concenter Biopharma.

Erez Aminov, chairman & CEO of MIRA, said, 'We are truly honoured to have Dr Angel on our team. His distinguished career across the pharmaceutical industry, from start-ups to big pharma, his exceptional scientific skills and his dedication to pharmaceutical innovation will help propel our promising pre-clinical drug candidates forward. His expertise will be invaluable as we move our product candidates towards INDs and through the clinical trial and regulatory approval process and also as we seek to expand our product candidate portfolio.'